Month: August 2023

VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) (“Liberty Gold” or the “Company”), is pleased to announce its financial and operating results for the six months ended June 30, 2023. All amounts are presented in United States dollars unless otherwise stated. SECOND QUARTER OF 2023 AND RECENT HIGHLIGHTSAnnounced the appointment of Wendy Louie to the Board and the appointment of Robert Pease as Chairman. Ms. Louie is a Canadian Chartered Professional Accountant (CPA, CA) with over 25 years of diverse financial and leadership experience with a focus on the mining industry. Mr. Pease has been on the board of Liberty Gold since its inception.At the Black Pine project (“Black Pine”), we:Announced a new discovery area “Rangefront South” located approximately two...

Successful restructuring plan transforms Xcel Brands into a modern, asset light consumer products and livestream/social commerce platform, realizing $13 million in annualized cost savings. Executed Master licenses for Judith Ripka, Halston and C Wonder brands with Jewelry TV (JTV), G-III Apparel Group and One Jeanswear Group, respectively. Revenues of $6.8 million for the quarter, an increase of $0.7 million (+12.1%) and $2.7 million (+66.8%) as compared to the quarters ended March 31, 2023, and December 31, 2022, respectively. GAAP net loss of $3.5 million for the quarter, compared with GAAP net loss of $5.6 million and $6.0 million in the quarters ended March 31, 2023, and December 31, 2022, respectively. Adjusted EBITDA of ($0.9) million for the quarter, compared with Adjusted EBITDA of ($2.0) million and ($5.9) million in the quarters...

Second Quarter 2023 Revenue Increased $18.0 million or 8.1% Over Second Quarter 2022 Gross Margin Improved by 190 basis points Over Second Quarter 2022 SUGAR LAND, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) — Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights1:Increased revenues to $239.5 million, up 8% over the 2022 second quarter. Improved gross margin to $60.9 million and 25.4% of revenue, up roughly 190 basis points from the 2022 second quarter. Reported net loss of $15.8 million, an improvement of $12.4 million over the 2022...

PLEASANTON, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc (Nasdaq: HCTI) (“HCTI” or the “Company”), a leader in digital transformation solutions including managed services, cloud enablement, cybersecurity, data analytics, and AI data processing for the healthcare and life sciences industries, today announced results for the second quarter of 2023 ended June 30, 2023. Thyagarajan Ramachandran, CFO of Healthcare Triangle, said, “We had a productive quarter focused on marketing and customer acquisition strategies along with platform development initiatives aimed at expanding our revenue streams. Operating margins were resilient within an uncertain macro environment reflecting our continued focus on cost optimization. Our priorities for the second half of 2023 are focused on building traction for key...

U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023 BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update. “We are excited about this week’s announcement of...

– First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 – – Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal model; Phase 2a trial in epilepsy planned to initiate in 2024 – – Agreement reached with U.S. FDA on study design and analysis approach for Phase 3 safety study of IV tramadol – MIAMI, Aug. 10, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2023. “Avenue continues to make significant progress across...

Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated patients (n=8) have exceeded historical median progression-free survival INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023. The Phase 2 trial (NCT05664243) will initially enroll newly diagnosed GBM patients in the autologous setting. The primary endpoint of the study is overall survival (OS); secondary endpoints include tolerability, progression-free survival (PFS), overall response rate (ORR) and time to progression (TTP) Promising preclinical data in ovarian cancer announced at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting underscores the synergistic potential of DeltEx gamma-delta T cells and chemotherapy...

Second Quarter Revenues Were $37.8 million and Gross Margin Expanded to 53% Year-to-Date Net Loss Attributable to UpHealth, Inc. Improved 9% to $27.2 million Year-to-Date Adjusted EBITDA Improved by $9.2 million to $11.8 million Closed Strategic Sale of Innovations Group, Inc. for $56.0 million Completed Repurchase of $10.3 Million of Convertible Debt Increasing Full Year 2023 Outlook DELRAY BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) — UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the second quarter ended June 30, 2023. UpHealth Chief Executive Officer Sam Meckey said, “During the second quarter we delivered results I am very proud of...